去甲腎上腺素再攝取抑制劑

去甲腎上腺素再攝取抑製劑正腎上腺素再攝取抑製劑NRIsNRI)為一種藥物抑製去甲腎上腺素的攝取。該藥通過阻斷或減緩去甲腎上腺素的再攝取而發揮作用。[1]而去甲腎上腺素為腦中調節注意力、搏動性和活動水平的重要物質,該藥對治療注意力缺陷多動症(ADHD)有明顯的作用。

現有的去甲腎上腺素再攝取抑製劑

普通

  • 阿托莫西汀
  • Amedalin (UK-3540-1)
  • CP-39,332
  • Daledalin (UK-3557-15)
  • Edivoxetine (LY-2216684)
  • Esreboxetine
  • Lortalamine (LM-1404)
  • 馬吲哚 (Mazanor, Sanorex)
  • Nisoxetine (LY-94,939)
  • 瑞波西汀 (Edronax, Vestra)
  • Talopram (Lu 3-010)
  • Talsupram (Lu 5-005)
  • Tandamine (AY-23,946)
  • Viloxazine (Vivalan)

另類

  • 安非他酮 (Wellbutrin, Zyban)
  • Ciclazindol (Wy-23,409)
  • Manifaxine (GW-320,659)
  • Radafaxine (GW-353,162)
  • Tapentadol (Nucynta)
  • Teniloxazine (Lucelan, Metatone)

參考

  1. . [2012-05-18]. (原始内容存档于2016-02-16).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.